Evidence map›Paper›PMID 34134728›Full record

ReviewMalaria journal2021

Malaria epidemiology and anti-malarial drug efficacy in Guinea: a review of clinical and molecular studies.

Mahamoud Sama Cherif, Prabin Dahal, Abdoul Habib Beavogui, Alexandre Delamou, Eugene Kaman Lama, Alioune Camara, Mamadou Pathe Diallo

Open access · goldAbstract readReview
In one paragraph

Review in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pediatric MixedChildren (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 4 countries.

Mahamoud Sama CherifFaculty of Sciences and Health Technics, Gamal Abdel Nasser University of Conakry, Conakry, Guinea. msamafr@gmail.com.ORCID http://orcid.org/0000-0002-4768-9234
Prabin DahalCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2158-846X
Abdoul Habib BeavoguiFaculty of Sciences and Health Technics, Gamal Abdel Nasser University of Conakry, Conakry, Guinea.
Alexandre DelamouFaculty of Sciences and Health Technics, Gamal Abdel Nasser University of Conakry, Conakry, Guinea.
Eugene Kaman LamaNational Malaria Control Programme (NMCP), Conakry, Guinea.
Alioune CamaraNational Malaria Control Programme (NMCP), Conakry, Guinea.
Mamadou Pathe DialloFaculty of Sciences and Health Technics, Gamal Abdel Nasser University of Conakry, Conakry, Guinea.
Gamal Abdel Nasser University of Conakry · GNUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria is one of the leading causes of mortality and morbidity in Guinea. The entire country is considered at risk of the disease. Transmission occurs all year round with peaks occurring from July through October with Plasmodium falciparum as the primary parasite species. Chloroquine (CQ) was the first-line drug against uncomplicated P. falciparum in Guinea until 2005, prior to the adoption of artemisinin-based combination therapy (ACT). In this review, data on therapeutic efficacy of CQ and artemisinin-based combinations reported in published literature is summarized. Against CQ, a failure rate of 27% (12/44) was reported in a study in 1992; a median failure rate of 15.6% [range: 7.7-28.3; 8 studies] was observed during 1996-2001, and 81% (17/21) of the patients failed to clear parasitaemia in a study conducted in 2007. For artemisinin-based combinations, three published studies were identified (1495 patients; 2004-2016); all three studies demonstrated day 28 polymerase chain reaction corrected efficacy > 95%. One study characterized kelch-13 mutations (389 tested; samples collected in 2016) with no evidence of mutations currently known to be associated with artemisinin resistance. The impact of the ongoing COVID-19 pandemic and widespread usage of counterfeit medicines are immediate challenges to malaria control activities in Guinea.

Indexed as

AntimalarialsCOVID-19GuineaHumansMalaria, FalciparumSARS-CoV-2AntimalarialsArtemisinin-based combination therapyEfficacyGuineaMalariaPlasmodium falciparumResistance

Identifiers

PMID34134728
PMCPMC8206902
OpenAlexW3169941924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.